Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study

Blood (2025) 146 (Supplement 1): 5274.

https://doi.org/10.1182/blood-2025-5274

Published: 2025

Journal Articles

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Claudia Nuñez-Torron stock, Carlos Jiménez, Fernando Martín Moro, Juan Marquet, Miguel Piris-Villaespesa, Clara Lopez Hernandez, Alejandro Luna, Valentín García Gutiérrez, Sr., Anabelle Chinea, Maria Gemma Moreno Jimenez, Javier López, Pilar Herrera Puente

Blood (2024) 144 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2024-210576

Published: 2024

Journal Articles

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2024-205717

Published: 2024

Journal Articles

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Lucia Bolea, Alejandro Luna, Enrique Blanco, Valentín García Gutiérrez, Sr., Anabelle Chinea, Begoña Hijono, Maria Luisa Palacios-Berraquero, Pablo Palomo Rumschisky, Blanca De Felipe, Lucía Pérez-Lamas, Carlos Jiménez, Beatriz Astibia Mahillo, Alejandro Zurdo-Castronuño, Maria Piñero, Rut Corrales, Pilar Herrera, Javier López

Blood (2024) 144 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2024-206026

Published: 2024

Journal Articles

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 598.

https://doi.org/10.1182/blood-2024-205686

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Pilar Lancho Lavilla, Miguel Lopez-Esteban, Javier Ortiz-Alonso, Gracia Fajardo-Tórtola, Patricia Font Lopez, Marina Gomez Llobell, Jose Antonio Serra Resach, Ana Perez-Corral, Isabel Regalado Artamendi, Mónica Ballesteros Andrés, Carolina Martinez-Laperche, Gloria Figaredo Garcia-Mina, Raquel Fernández González, Carlos Jiménez, Diego Conde Royo, Cristina Pascual Izquierdo, María Teresa Vidán, Ramon García-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2024-203872

Published: 2024

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Correlation of TCR Repertoire Diversity with Myeloid Gene Mutations in Chronic and Advanced Phase Myeloproliferative Neoplasms

Miguel Piris-Villaespesa, Juan Marquet, Val Fernandez-Lanza, Valentín García Gutiérrez, Carlos Jimenez, Francisco J del Castillo, Gloria Muñoz, Javier López

Blood (2023) 142 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2023-189836

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Blood (2023) 142 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2023-173311

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Antonio Perez, María Ovidia López, Rocío González-Sacristán, Mercedes Gasior, Antonio Marcos, Raquel De Paz Arias, José María Alonso, Carmen Mestre-Durán, Karima Al-Akioui, Cristina Ferreras, Antonio Balas, Jose Luis Vicario, Carlos Solano, Belén Estébanez, Esther Ramos-Boluda, Carlos Jiménez, Francisco Hernández-Oliveros

Blood (2022) 140 (Supplement 1): 10484–10485.

https://doi.org/10.1182/blood-2022-168909

Published: 2022

Journal Articles

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Blood (2021) 138 (Supplement 1): 2607.

https://doi.org/10.1182/blood-2021-149147

Published: 2021

Journal Articles

The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Claudia Nunez-Torron, Carlos Jimenez Chillon, Fernando Martin Moro, Alejandro Luna, Adolfo Saez, Kyra Velázquez-Kennedy, Juan Marquet Palomanes, Miguel Piris-Villaespesa, Valentín Garcia-Gutiérrez, Anabelle Chinea, Gemma Moreno Jiménez, Javier López Jiménez, Pilar Herrera

Blood (2021) 138 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2021-149494

Published: 2021

Journal Articles

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Daniel Esteban, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Paola Charry, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142740

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Correlation of TCR Repertoire Diversity with Myeloid Gene Mutations in Chronic and Advanced Phase Myeloproliferative Neoplasms

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only